Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
5.16
-0.06 (-1.15%)
At close: Nov 7, 2025, 4:00 PM EST
5.26
+0.10 (1.94%)
After-hours: Nov 7, 2025, 4:28 PM EST
Karyopharm Therapeutics Revenue
Karyopharm Therapeutics had revenue of $44.04M in the quarter ending September 30, 2025, with 13.57% growth. This brings the company's revenue in the last twelve months to $142.53M, down -3.98% year-over-year. In the year 2024, Karyopharm Therapeutics had annual revenue of $145.24M, down -0.55%.
Revenue (ttm)
$142.53M
Revenue Growth
-3.98%
P/S Ratio
0.31
Revenue / Employee
$510,860
Employees
279
Market Cap
87.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 145.24M | -796.00K | -0.55% |
| Dec 31, 2023 | 146.03M | -11.04M | -7.03% |
| Dec 31, 2022 | 157.07M | -52.75M | -25.14% |
| Dec 31, 2021 | 209.82M | 101.73M | 94.12% |
| Dec 31, 2020 | 108.09M | 67.19M | 164.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KPTI News
- 4 days ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 days ago - Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress - PRNewsWire
- 12 days ago - Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025 - PRNewsWire
- 4 weeks ago - Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026 - Benzinga
- 4 weeks ago - Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis - PRNewsWire
- 2 months ago - Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis - PRNewsWire
- 3 months ago - Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript - Seeking Alpha